Cumberland Pharmaceuticals (CPIX) Reports Q1 EPS of $0.09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Cumberland Pharmaceuticals Reports First Quarter 2015 Financial Results
May 7, 2015 4:05 PM EDTNASHVILLE, Tenn., May 7, 2015 /PRNewswire/ --Â Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2015 financial results with Adjusted Earnings up 72% to $1.6 million or $0.09 per share. Net revenues were $8.7 million, compared to $8.1 million for the prior year period.
As of March 31, 2015 the Company had $53 million in cash and investments, approximately $92 million in total assets, and no debt. Cumberland also had $44 million in tax net operating loss carryforwards, resulting from the... More
